Back to results
US 6,297,238 B1Granted
Therapeutic agents
AssigneeBASF SE
InventorsKevin Doyle, Paul Rafferty, Robert Steele, Allyson Turner, David Wilkins, Lee Arnold
Life of this patent
Estimating the term…
Abstract
This invention realtes to compounds formula I and pharmaceutically acceptable salts thereof, which are inhibitors of protein kinase activity, pharmaceutical compositions thereof and provesses for their preparation.
Claims42
Compounds formula I
- or racemic-diastereomeric mixtures, optical isomers, pharmaceutically-acceptable salts, prodrugs or biologically active metabolites thereof in which
- L1 represents a group of formula (E)s(CH2)q in which E represents NR24, O or S, s is 0 or 1 and q is an integer from 0 to 6, provided that when s is 1 q is at least 1, in which the alkylene chain is optionally substituted by one or more of the following:
- a C1-6 alkyl group optionally substituted by one or more hydroxy, halo or optionally substituted amino;
- a C1-6 alkoxy group optionally substituted by one or more hydroxy, halo or optionally substituted amino;
- hydroxy;
- halo;
- or optionally substituted amino;
- A represents CONH, NHCO, SO2NH, NHSO2, or NR25;
- L2 represents C(═O), C(═NH), or a group of formula (CH2)r in which r is an integer from 0 to 6 in which the alkylene chain is optionally substituted by one or more of the following:
- a C1-6 alkyl group optionally substituted by one or more hydroxy, halo or optionally substituted amino;
- a C1-6 alkoxy group optionally substituted by one or more hydroxy, halo or optionally substituted amino;
- hydroxy;
- halo;
- or optionally substituted amino;
- R2 represents a C1-6 alkyl group optionally substituted by one or more of the following:
- halo, hydroxy, C1-6 alkoxy or optionally substituted amino;
- a C1-6 alkoxy group optionally substituted by one or more of the following:
- halo, hydroxy, C1-6 alkoxy or optionally substituted amino;
- or R2 is halo, hydroxy, cyano, nitro, carbamoyl, a C1-6 alkanoylgroup, a (C1-6 alkoxy)carbonyl group or optionally substituted amino;
- n represents 0,1,2 or 3
- X represents a) substituted methylene b) carbonyl, c) oxygen, d) a group of formula —C═NOR7 in which R7 represents H or a C1-6 alkyl group, e) a group of formula NR8 in which R8 represents H, an optionally substituted C1-6 alkyl group or optionally substituted phenyl, f) a group of formula (CH2)n in which n is 1, 2 or 3, or g) a group of formula S(O)p in which p is 0, 1 or 2;
- R3, R4, R5 and R6 independently represent a) H, b) halo, c) C1-6 alkyl group optionally substituted by one or more of the following:
- hydroxy, a C1-6 alkoxy group, halo or an optionally substituted amino group d) a C1-6 alkoxy group optionally substituted by one or more of the following:
- hydroxy;
- a C1-6 alkoxy group;
- halo;
- or an optionally substituted amino group provided that these groups are not attached to the carbon which is attached to the oxygen of the alkoxy group;
- e) optionally substituted phenoxy, f) hydroxy, g) a group formula CORa in which Ra represents hydroxy, a C1-6 alkoxy group or Ra represents an optionally substituted amino group, h) an optionally substituted amino group i) a C1-6 alkanoyl group j) nitro, k) optionally substituted phenyl C1-6 alkyl, l) optionally substituted phenyl C1-6 alkoxy m) cyano;
- or o) a C2-4 alkenyl group or a C2-4 alkynyl group each of which is optionally substituted by phenyl which is optionally substituted by one or more of the following:
- a C1-6 alkyl group, a C1-6 alkoxy group or halo;
- and
- 1) when A is SO2NH, or NHSO2:
- R1 represents a) optionally substituted phenyl b) optionally substituted heteroaryl, c) a five, six, seven or eight membered saturated heterocyclic ring containing a nitrogen atom which optionally contains an additional hetero atom selected from O, S or N and is optionally substituted by a C1-6 alkyl group wherein said saturated ring may be attached through carbon or a hetero atom d) an optionally substituted amino group or e) a C1-6 alkoxy group;
- 2) when A represents CONH or NHCO:
- R1 represents a) phenyl substituted by nitro or one or more C1-6 alkoxy groups optionally substituted by one or more of the following:
- halo, hydroxy, C1-6 alkoxy or optionally substituted amino b) optionally substituted heteroaryl or c) a five, six, seven or eight membered saturated heterocyclic ring containing a nitrogen atom which optionally contains an additional hetero atom selected from O, S or N and is optionally substituted by a C1-6 alkyl group wherein said saturated ring is attached through a carbon atom or d) a C1-6 alkoxy group;
- 3) when A represents a group NR25 and q is at least 1:
- R1 represents a) optionally substituted phenyl b) optionally substituted heteroaryl or c) optionally substituted amino group;
- and
- 4) when A represents a group NR25 and q is 0 and s is 0 then R1 represents optionally substituted heteroaryl;
- R24 and R25 independently represent H;
- a C1-6 alkyl group optionally substituted by one or more of the following:
- hydroxy, a C1-6 alkoxy group, halo or an optionally substituted amino group;
- a C1-6 alkanoyl group or a C1-6 alkylsulphonyl group;
- provided that no two hereto atoms are attached to the same sp3 hybridized carbon atom.
42 more elements
A compound selected from:
- 4-(1,4-dihydroindeno[1,2-c]pyrazole)-N-(4-pyridyl)benzylamine
- N-[4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenyl]benzenesulphonamide
- 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-N-(2-methoxyethyl)benzamide
- 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-N-(4-nitrophenyl)benzamide
- 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)imidazol-1-ylacetanilide
- 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-N-[2-(imidazol-1-yl)ethyl]aniline
- 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-N-(2-morpholinoethyl)benzenesulphonamide
- 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-N-(2-methoxyethyl)benzenesulphonamide
- N-[2-(N,N-diethylamino)ethyl]-4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzylamine
- N-[2-(N,N-diethylamino)ethyl]-4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzenesulphonamide
- 4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-N-(2-morpholinoethyl)benzylamine
- N-(4-ethoxyphenyl)-4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)benzylamine
- (S)-4-(1,4-dihydroindeno[1,2-c]pyrazol-3-yl)-N-(pyrrolidin-2-ylmethyl)benzamide
- 4-(1H-[1]benzothieno[3,2-c]pyrazol-3-yl)-N-[3-(imidazol-1-yl)propyl]benzylamine
- 4-(1H-[1]benzothieno[3,2-c]pyrazol-3-yl)-N-(2-morpholinoethyl)benzylamine,
- and racemic-diastereomeric mixtures, optical isomers, pharmaceutically-acceptable salts, prodrugs and biologically active metabolites thereof.
13 more elements
A compound of the following formula wherein X, R and R′ are selected form:
- X NRR′ CH2 S S CMe2 CMe2 SO2 S CH2 C═O O S═O S S S S CH2 CH2 CH2 S S S S S S S CH2 CH2 CH2 S S S S S S S S S CH2 CH2 CH2
- and racemic-diastereomeric mixtures, optical isomers, pharmaceutically-acceptable salts, prodrugs and biologically active metabolites thereof.
Dependencies are inferred from the claim text.